This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-22. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In North Africa, the Wehrmacht shipped in fresh fruit from Italy and Greece to supplement its troops' rations, even during the Great Famine in Greece. The Imperial Japanese Army and Navy received rather basic rations, usually consisting of rice with barley, meat or fish, pickled or fresh vegetables, umeboshi, soy sauce, miso or bean paste, and green tea. The rations were intended to be eaten with other foraged food. Japanese soldiers were also issued emergency rations. The standard emergency ration, intended to last for five days, included a small sack of rice, package of compact food, package of hardtack, one-half pound (230 g) of hard candy, can of tea, and vitamin pills. Japanese soldiers also hunted dogs, goats, and other small animals to add to their emergency rations. In the Burma campaign, two types of emergency rations were used, "A" rations intended for three days consisting of 19 ounces (540 g) of rice and a small can of beef and vegetables, and "B" rations intended for one day consisting of three bags of hard biscuits. They were meant to be eaten only upon orders from a commanding officer when the unit was separated from its supply column. Japanese soldiers were often undersupplied. Japanese commanders had a cavalier attitude to food supplies for their troops and supply lines were often not protected. As a result, about 60% of Japanese military deaths during the war were due to starvation.
Churchill is a man with an out-of-date political idea—that of the European balance of power. It no longer belongs to the sphere of realities. And yet it's because of this superstition that Churchill stirred England up to war. On another occasion he added: Without the Wehrmacht, a "wave would have swept over Europe that would have taken no care of the ridiculous British idea of the balance of power in Europe in all its banality and stupid tradition—once and for all." In fact, Churchill shortly adopted a similar view: Our Russian friends and Allies, he spoke in 1946, most admire strength and least respect military weakness. "For that reason the old doctrine of a balance of power is unsound. We cannot afford … to work on narrow margins, offering temptations to a trial of strength." If the Western Democracies do not stand together "then indeed catastrophe may overwhelm us all." If, however, "the population of the English-speaking Commonwealths be added to that of the United States with all that such co-operation implies in the air, on the sea, all over the globe and in science and in industry, and in moral force, there will be no quivering, precarious balance of power to offer its temptation to ambition or adventure. On the contrary, there will be an overwhelming assurance of security."
== Early life and education == Susan Epstein (later changed to Leeman by marriage) was born on May 9, 1930, in Chicago, Illinois. Her mother was born in the United States and her father had emigrated from Russia to New York City. Her father was an academic metallurgist and her mother attended college at George Washington University at a time when few other women did. Susan also had one older brother named Henry. When Susan was six weeks old she and her family moved to Columbus, Ohio, and then to Bethlehem, Pennsylvania when she was six years old. There she grew up a part of a middle class Jewish family. She often faced discrimination in the form of antisemitism and sexism as she pursued a career in science. During her childhood Leeman attended Hebrew School and was a Girl Scout. She decided to attend Goucher College, which was an all-girls’ school at the time, from which she received a bachelor's degree in physiology in 1951. She then applied to and was accepted by Harvard Medical School, but her academic program was administered through Radcliffe College. Thus, Radcliffe College was where she received her master's degree and PhD from in 1954 and 1958 respectively. Leeman was the only woman in her class to make it through the graduate program and continue a career in science. During her time in graduate school she was introduced to the field of neuroendocrinology, within which she was able to explore her passion for how the mind connects to the body.
Sources: en.wikipedia.org
== Diagnostic == Dozens of congenital metabolic diseases are now detectable by newborn screening tests, especially expanded testing using mass spectrometry. Gas chromatography–mass spectrometry-based technology with an integrated analytics system has now made it possible to test a newborn for over 100 mm genetic metabolic disorders. Because of the multiplicity of conditions, many different diagnostic tests are used for screening. An abnormal result is often followed by a subsequent "definitive test" to confirm the suspected diagnosis.
=== Diagnostic === Intravenous injection of TRH has been used for diagnostic purposes in the context of the TRH test; administration of exogenous TRH can be used to determine whether hypothyroidism is of hypothalamic or hypophyseal etiology. However, this diagnostic approach has been superseded by ultrasensitive TSH assays and is nowadays only seldom employed.
==== Nixon's role reviewed ==== Decades later, a controversial quote attributed to John Ehrlichman, Nixon's domestic policy advisor, claimed that the war on drugs was fabricated to undermine the anti-war movement and African-Americans. In a 2016 Harper's cover story, Ehrlichman, who died in 1999, was quoted from journalist Dan Baum's 1994 interview notes: "... by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did." The veracity of the quote was challenged by Ehrlichman's children, and Nixon-era officials. In the end, the increasingly punitive reshaping of US drug policy by later administrations was most responsible for creating some of the conditions Ehrlichman described. In a 2011 commentary, Robert DuPont, Nixon's drug czar, argued that the Comprehensive Drug Abuse Act had represented a degree of drug reform. He noted that the act had rolled back mandatory minimum sentencing and balanced the "long-dominant law enforcement approach to drug policy, known as 'supply reduction'" with an "entirely new and massive commitment to prevention, intervention and treatment, known as 'demand reduction'". Thus, Nixon was not in fact the originator of what came to be called the "war on drugs".
A 2023 meta-analysis including 13 cardiovascular outcome trials reported that SGLT2 inhibitors reduce the risk for three-point major adverse cardiovascular events, especially in subjects with an estimated glomerular filtration rate (eGFR) below 60 mL/min, whereas GLP-1 receptor agonists were more beneficial in people with higher eGFRs. Likewise, the relative risk reduction of SGLT-2 inhibitor treatment was larger in populations with a higher proportion of albuminuria, but this relationship was not observed for GLP-1 receptor agonists. This suggests differential use of the two substance classes in people with preserved and reduced renal function or with and without diabetic nephropathy, respectively. GLP-1 agonists and SGLT2 inhibitors work to reduce HbA1c by different mechanisms and can be combined for enhanced effects. They may provide additive cardioprotective effects. The US Food and Drug Administration has not approved GLP-1 agonists for type 1 diabetes, but they have been used off-label in addition to insulin.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.